![]() | Only 14 pages are availabe for public view |
Abstract Sorafenib (Sor) is a multi-kinase inhibitor, it is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. Taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance the function of leukocytes. Aim of the study: The present study aimed to investigate the immunological aspects of Sor, Taurine as well as after combination on human hepatocytes. Materials and Methods: HepG2 cell line was cultured to determine IC50 using SRB assay. The levels of TGF-Ý and IL-10 released in culture media of the cells were determined by ELISA |